Volume 11, Issue 3 pp. 291-295

Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A

Lars Pape

Lars Pape

Department of Pediatric Nephrology, Medical School of Hannover, Hannover, Germany

Search for more papers by this author
Thurid Ahlenstiel

Thurid Ahlenstiel

Department of Pediatric Nephrology, Medical School of Hannover, Hannover, Germany

Search for more papers by this author
Jochen H. H. Ehrich

Jochen H. H. Ehrich

Department of Pediatric Nephrology, Medical School of Hannover, Hannover, Germany

Search for more papers by this author
Gisela Offner

Gisela Offner

Department of Pediatric Nephrology, Medical School of Hannover, Hannover, Germany

Search for more papers by this author
First published: 06 April 2007
Citations: 32
Lars Pape, Department of Pediatric Nephrology, Medical School of Hannover, Carl-Neuberg-Straße 1, D-30625 Hannover, Germany
Tel.: +49 511 532 5706
Fax: +49 511 530 4830
E-mail: [email protected]

Abstract

Abstract:   Until now there have been no good therapeutic options in children with biopsy-proven transplant nephropathy (TN) and loss of glomerular filtration rate (GFR) while receiving cyclosporine A (CsA), mycophenolate mofetil (MMF) and prednisolone (Pred). In 13 kidney transplanted children (mean age 13 yr, SD 4) with CsA/MMF/Pred immunosuppression, renal biopsy revealed significant TN. MMF was discontinued, CsA dose was reduced to 50% and Everolimus was started (1.6 mg/m2/day). Pred was stopped in 10 of 13 patients. The mean GFR was 55 mL/min/1.73 m2 (SD 24) one yr before switch, 45 mL/min/1.73 m2 (SD 16, p < 0.05) at the time of switch and 47 mL/min/1.73 m2 (SD 18, p < 0.05) 12 months later. There were no severe side-effects or acute rejections. Lactate dehydrogenase, cholesterol, creatine kinase, and U-albumin/creatinine ratio did not increase significantly. After six months, the mean certican-C0 level was 4.0 μg/L (SD 1.5) and mean CsA-C0 level was 52 ng/mL (SD 23). The GFR of transplanted kidneys in children with TN improved by changing immunosuppression from CsA/MMF/Pred to everolimus and low-dose CsA.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.